Klein S, Gastaldelli A, Yki-Järvinen H, et al. Why does obesity cause diabetes? Cell Metab. 2022;34(1):11–20.

Article  CAS  PubMed Central  Google Scholar 

Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302–8.

Article  CAS  PubMed Central  Google Scholar 

Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–81.

Article  Google Scholar 

Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.

Article  CAS  Google Scholar 

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.

Article  CAS  PubMed Central  Google Scholar 

Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.

Article  CAS  Google Scholar 

Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for primary and secondary prevention of cardiovascular events. Circulation. 2018;137(4):323–34.

Article  CAS  PubMed Central  Google Scholar 

Ardiles LG. Obesity and renal disease: benefits of bariatric surgery. Front Med. 2023;10:1134644.

Article  Google Scholar 

Cohen RV, Pereira TV, Aboud CM, et al. Effect of gastric bypass vs best medical treatment on early-stage chronic kidney disease in patients with type 2 diabetes and obesity: a randomized clinical trial. JAMA Surg. 2020;155(8):1–11.

Article  Google Scholar 

Cloyd JM, Ma Y, Morton JM, et al. Does chronic kidney disease affect outcomes after major abdominal surgery? Results from the National Surgical Quality Improvement Program. J Gastrointest Surg. 2014;18(3):605–12.

Article  Google Scholar 

Martin WP, White J, López-Hernández FJ. Metabolic surgery to treat obesity in diabetic kidney disease, chronic kidney disease, and end-stage kidney disease; what are the unanswered questions? Front Endocrinol. 2020;17:11.

Google Scholar 

Cohen RV, Pereira TV, Aboud CM, et al. Gastric bypass versus best medical treatment for diabetic kidney disease: 5 years follow up of a single-centre open label randomised controlled trial. eClinicalMedicine. 2022;53:101725.

Article  PubMed Central  Google Scholar 

Katsogiannos P, Kamble PG, Boersma GJ, et al. Early changes in adipose tissue morphology, gene expression, and metabolism after RYGB in patients with obesity and T2D. J Clin Endocrinol Metab. 2019;104(7):2601–13.

Article  Google Scholar 

Almby KE, Katsogiannos P, Pereira MJ, et al. Time course of metabolic, neuroendocrine, and adipose effects during 2 years of follow-up after gastric bypass in patients with type 2 diabetes. J Clin Endocrinol Metab. 2021;106(10):E4049–61.

Article  PubMed Central  Google Scholar 

Casajoana A, Pujol J, Garcia A, et al. Predictive value of gut peptides in T2D remission: randomized controlled trial comparing metabolic gastric bypass, sleeve gastrectomy and greater curvature plication. Obes Surg. 2017;27(9):2235–45.

Article  Google Scholar 

Ceperuelo-Mallafre V, Llaurado G, Keiran N, et al. Preoperative circulating succinate levels as a biomarker for diabetes remission after bariatric surgery. Diabetes Care. 2019;42(10):1956–65.

Article  CAS  Google Scholar 

Casajoana A, Guerrero-Pérez F, García Ruiz de Gordejuela A, et al. Role of gastrointestinal hormones as a predictive factor for long-term diabetes remission: randomized trial comparing metabolic gastric bypass, sleeve gastrectomy, and greater curvature plication. Obes Surg. 2021;31(4):1733–44.

Article  Google Scholar 

Guerrero-Pérez F, Casajoana A, Gómez-Vaquero C, et al. Changes in bone mineral density in patients with type 2 diabetes after different bariatric surgery procedures and the role of gastrointestinal hormones. Obes Surg. 2020;30(1):180–8.

Article  Google Scholar 

Guerrero-Pérez F, Casajoana A, Gómez-Vaquero C, et al. Long-term effects in bone mineral density after different bariatric procedures in patients with type 2 diabetes: outcomes of a randomized clinical trial. J Clin Med. 2020;9(6):1–15.

Article  Google Scholar 

Constantin A, Dumitrescu M, Nemecz M, et al. Sera of obese type 2 diabetic patients undergoing metabolic surgery instead of conventional treatment exert beneficial effects on beta cell survival and function: results of a randomized clinical study. Obes Surg. 2019;29(5):1485–97.

Article  Google Scholar 

Courcoulas AP, Goodpaster BH, Eagleton JK, et al. Surgical vs medical treatments for type 2 diabetes mellitus. JAMA Surg. 2014;149(7):707.

Article  PubMed Central  Google Scholar 

Courcoulas AP, Belle SH, Neiberg RH, et al. Three-year outcomes of bariatric surgery vs lifestyle intervention for type 2 diabetes mellitus treatment. JAMA Surg. 2015;150(10):931.

Article  PubMed Central  Google Scholar 

Courcoulas AP, Gallagher JW, Neiberg RH, et al. Bariatric surgery vs lifestyle intervention for diabetes treatment: 5-year outcomes from a randomized trial. J Clin Endocrinol Metab. 2020;105(3):866–76.

Article  PubMed Central  Google Scholar 

Davies N, O’Sullivan JM, Plank LD, et al. Gut microbial predictors of type 2 diabetes remission following bariatric surgery. Obes Surg. 2020;30(9):3536–48.

Article  Google Scholar 

Hofsø D, Fatima F, Borgeraas H, et al. Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(12):912–24.

Article  Google Scholar 

Hofsø D, Hillestad TOW, Halvorsen E, et al. Bone mineral density and turnover after sleeve gastrectomy and gastric bypass: a randomized controlled trial (Oseberg). J Clin Endocrinol Metab. 2021;106(2):501–11.

Article  Google Scholar 

Fatima F, Hjelmesæth J, Birkeland KI, et al. Gastrointestinal hormones and β-cell function after gastric bypass and sleeve gastrectomy: a randomized controlled trial (Oseberg). J Clin Endocrinol Metab. 2022;107(2):E756–66.

Article  Google Scholar 

Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia. JAMA. 2013;309(21):2240.

Article  CAS  PubMed Central  Google Scholar 

Ikramuddin S, Billington CJ, Lee WJ, et al. Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study): 2-year outcomes of a 5-year, randomised, controlled trial. Lancet Diabetes Endocrinol. 2015;3(6):413–22.

Article  PubMed Central  Google Scholar 

Nguyen KT, Billington CJ, Vella A, et al. Preserved insulin secretory capacity and weight loss are the predominant predictors of glycemic control in patients with type 2 diabetes randomized to Roux-en-y gastric bypass. Diabetes. 2015;64(9):3104–10.

Article  CAS  PubMed Central  Google Scholar 

Ikramuddin S, Korner J, Lee WJ, et al. Durability of addition of Roux-en-Y gastric bypass to lifestyle intervention and medical management in achieving primary treatment goals for uncontrolled type 2 diabetes in mild to moderate obesity: a randomized control trial. Diabetes Care. 2016;39(9):1510–8.

Article  CAS  PubMed Central  Google Scholar 

Jahansouz C, Xu H, Kizy S, et al. Serum FABP4 concentrations decrease after Roux-en-Y gastric bypass but not after intensive medical management. Surgery. 2019;165(3):571–8.

Article  Google Scholar 

Keidar A, Hershkop KJ, Marko L, et al. Roux-en-Y gastric bypass vs sleeve gastrectomy for obese patients with type 2 diabetes: a randomised trial. Diabetologia. 2013;56(9):1914–8.

Article  Google Scholar 

Lau E, Belda E, Picq P, et al. Gut microbiota changes after metabolic surgery in adult diabetic patients with mild obesity: a randomised controlled trial. Diabetol Metab Syndr. 2021;13(1):1–15.

Article  Google Scholar 

Laurenius A, Wallengren O, Alaraj A, et al. Resolution of diabetes, gastrointestinal symptoms, and self-reported dietary intake after gastric bypass versus sleeve gastrectomy: a randomized study. Surg Obes Relat Dis. 2023;19(5):440–8.

Article  Google Scholar 

Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366(17):1577–85.

Article  CAS  Google Scholar 

Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015;386(9997):964–73.

Article  Google Scholar 

Mingrone G, Panunzi S, De Gaetano A, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2021;397(10271):293–304.

Article  Google Scholar 

Murphy R, Tsai P, Jüllig M, et al. Differential changes in gut microbiota after gastric bypass and sleeve gastrectomy bariatric surgery vary according to diabetes remission. Obes Surg. 2017;27(4